• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody-Drug Conjugate-Induced Pneumonitis: A Growing Threat.

作者信息

Chan Kathy L, Faiz Saadia A, Sheshadri Ajay

机构信息

Divisions of Critical Care, Pulmonary and Sleep Medicine, McGovern Medical School at UTHealth, Houston, TX, USA.

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

J Immunother Precis Oncol. 2025 Apr 10;8(2):141-142. doi: 10.36401/JIPO-25-X1. eCollection 2025 May.

DOI:10.36401/JIPO-25-X1
PMID:40242271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12001233/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e269/12001233/8aae2d9dcf87/10.36401_JIPO-25-X1-f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e269/12001233/8aae2d9dcf87/10.36401_JIPO-25-X1-f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e269/12001233/8aae2d9dcf87/10.36401_JIPO-25-X1-f01.jpg

相似文献

1
Antibody-Drug Conjugate-Induced Pneumonitis: A Growing Threat.抗体药物偶联物诱导的肺炎：日益严重的威胁。
J Immunother Precis Oncol. 2025 Apr 10;8(2):141-142. doi: 10.36401/JIPO-25-X1. eCollection 2025 May.
2
Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies.靶向肿瘤治疗所致药物相关性肺炎的进展
J Immunother Precis Oncol. 2024 Nov 1;7(4):272-282. doi: 10.36401/JIPO-24-12. eCollection 2024 Nov.
3
Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non-Small Cell Lung Cancer: A Case Report.新型类固醇方案治疗非小细胞肺癌中c-MET抗体药物偶联物所致无症状肺炎：一例报告
J Immunother Precis Oncol. 2025 Feb 14;8(2):108-112. doi: 10.36401/JIPO-24-29. eCollection 2025 May.
4
Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis.实体瘤患者中抗体药物偶联物相关肺炎的发病率：一项系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2023 Apr;184:103960. doi: 10.1016/j.critrevonc.2023.103960. Epub 2023 Mar 11.
5
Imaging of Drug-Related Pneumonitis in Oncology.肿瘤治疗相关肺炎的影像学表现。
Semin Respir Crit Care Med. 2022 Dec;43(6):887-898. doi: 10.1055/s-0042-1755569. Epub 2022 Oct 28.
6
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.曲妥珠单抗-美坦新偶联物致 ERBB2 阳性晚期实体瘤患者的间质性肺病/肺炎：系统评价。
Drugs. 2022 Jun;82(9):979-987. doi: 10.1007/s40265-022-01736-w. Epub 2022 Jun 27.
7
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China.中国多学科管理人表皮生长因子受体 2 抗体药物偶联物相关性间质性肺疾病/肺炎的临床最佳实践：专家共识。
Cancer. 2024 Sep 1;130(S17):3054-3066. doi: 10.1002/cncr.35475. Epub 2024 Aug 2.
8
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore.抗体药物偶联物所致间质性肺病或肺炎的优化监测、早期诊断及有效管理的临床最佳实践：新加坡的多学科团队方法
Expert Opin Drug Metab Toxicol. 2022 Dec;18(12):805-815. doi: 10.1080/17425255.2022.2162383. Epub 2023 Jan 12.
9
Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.免疫相关性肺炎与非小细胞肺癌患者接受抗程序性死亡 1 抗体治疗时存在预先存在的间质性肺病的相关性。
Cancer Immunol Immunother. 2020 Jan;69(1):15-22. doi: 10.1007/s00262-019-02431-8. Epub 2019 Nov 19.
10
Trastuzumab Deruxtecan‒Related Interstitial Lung Disease/Pneumonitis: Computed Tomography Imaging Patterns to Guide Diagnosis and Management.曲妥珠单抗德鲁替康相关的间质性肺疾病/肺炎：计算机断层扫描成像模式以指导诊断和管理
JCO Precis Oncol. 2023 Sep;7:e2300391. doi: 10.1200/PO.23.00391.

本文引用的文献

1
Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non-Small Cell Lung Cancer: A Case Report.新型类固醇方案治疗非小细胞肺癌中c-MET抗体药物偶联物所致无症状肺炎：一例报告
J Immunother Precis Oncol. 2025 Feb 14;8(2):108-112. doi: 10.36401/JIPO-24-29. eCollection 2025 May.
2
Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies.靶向肿瘤治疗所致药物相关性肺炎的进展
J Immunother Precis Oncol. 2024 Nov 1;7(4):272-282. doi: 10.36401/JIPO-24-12. eCollection 2024 Nov.
3
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis.
非小细胞肺癌患者接受免疫检查点抑制剂治疗后发生肺炎的长期临床、影像学和死亡率结局：一项回顾性分析。
Clin Lung Cancer. 2024 Nov;25(7):624-633.e2. doi: 10.1016/j.cllc.2024.07.017. Epub 2024 Aug 3.
4
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.曲妥珠单抗衍生物治疗人表皮生长因子受体 2 表达转移性乳腺癌相关间质性肺病/肺炎的真实世界观点和实践。
JCO Oncol Pract. 2023 Aug;19(8):539-546. doi: 10.1200/OP.22.00480. Epub 2023 May 19.
5
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.ADC毒性机制及提高ADC耐受性的策略。
Cancers (Basel). 2023 Jan 24;15(3):713. doi: 10.3390/cancers15030713.
6
Antibody drug conjugate: the "biological missile" for targeted cancer therapy.抗体药物偶联物：靶向癌症治疗的“生物导弹”。
Signal Transduct Target Ther. 2022 Mar 22;7(1):93. doi: 10.1038/s41392-022-00947-7.
7
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：ASCO 指南更新。
J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1.
8
Chronic immune checkpoint inhibitor pneumonitis.慢性免疫检查点抑制剂肺炎。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000840.
9
Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment.奥希替尼治疗期间出现的短暂无症状性肺部混浊。
J Thorac Oncol. 2016 Dec;11(12):2253-2258. doi: 10.1016/j.jtho.2016.08.144. Epub 2016 Sep 13.